AU2018334214A1 - A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof - Google Patents

A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof Download PDF

Info

Publication number
AU2018334214A1
AU2018334214A1 AU2018334214A AU2018334214A AU2018334214A1 AU 2018334214 A1 AU2018334214 A1 AU 2018334214A1 AU 2018334214 A AU2018334214 A AU 2018334214A AU 2018334214 A AU2018334214 A AU 2018334214A AU 2018334214 A1 AU2018334214 A1 AU 2018334214A1
Authority
AU
Australia
Prior art keywords
compound
sleep
subject
administered
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018334214A
Other languages
English (en)
Inventor
James J. Doherty
Jeffrey M. Jonas
Stephen Jay Kanes
Inderjit KAUL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AU2018334214A1 publication Critical patent/AU2018334214A1/en
Priority to AU2024205601A priority Critical patent/AU2024205601A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018334214A 2017-09-14 2018-09-14 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof Abandoned AU2018334214A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205601A AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US62/558,703 2017-09-14
US201862624680P 2018-01-31 2018-01-31
US201862624678P 2018-01-31 2018-01-31
US62/624,680 2018-01-31
US62/624,678 2018-01-31
US201862653189P 2018-04-05 2018-04-05
US62/653,189 2018-04-05
PCT/US2018/051048 WO2019055764A1 (en) 2017-09-14 2018-09-14 C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205601A Division AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Publications (1)

Publication Number Publication Date
AU2018334214A1 true AU2018334214A1 (en) 2020-03-26

Family

ID=65723895

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018334214A Abandoned AU2018334214A1 (en) 2017-09-14 2018-09-14 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AU2024205601A Pending AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205601A Pending AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Country Status (9)

Country Link
US (3) US20220110949A1 (cg-RX-API-DMAC7.html)
EP (3) EP4218767A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020534270A (cg-RX-API-DMAC7.html)
AU (2) AU2018334214A1 (cg-RX-API-DMAC7.html)
CA (1) CA3075872A1 (cg-RX-API-DMAC7.html)
IL (2) IL303083A (cg-RX-API-DMAC7.html)
MX (3) MX2020002889A (cg-RX-API-DMAC7.html)
TW (2) TW201919642A (cg-RX-API-DMAC7.html)
WO (1) WO2019055764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Also Published As

Publication number Publication date
US20250387414A1 (en) 2025-12-25
JP2023038310A (ja) 2023-03-16
MX2023010063A (es) 2023-09-06
EP4218767A1 (en) 2023-08-02
EP3681510A1 (en) 2020-07-22
CA3075872A1 (en) 2019-03-21
JP2020534270A (ja) 2020-11-26
MX2023010064A (es) 2023-09-06
EP4696301A3 (en) 2026-04-29
AU2024205601A1 (en) 2024-08-29
TW201919642A (zh) 2019-06-01
MX2020002889A (es) 2020-10-01
EP4696301A2 (en) 2026-02-18
WO2019055764A1 (en) 2019-03-21
US20230201224A1 (en) 2023-06-29
JP2024107137A (ja) 2024-08-08
IL303083A (en) 2023-07-01
IL273126A (en) 2020-04-30
TW202339764A (zh) 2023-10-16
US20220110949A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
US20250387414A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230192612A1 (en) Formulations of t-type calcium channel modulators and methods of use thereof
AU2015336463B2 (en) Compositions and methods for treating insomnia
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
RU2718906C2 (ru) Способы и композиции для лечения гипергидроза
KR20230018384A (ko) T-형 칼슘 채널 조정제의 사용 방법
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
KR20250165616A (ko) 고함량 단일 투여 단위 제형 및 이의 사용 방법
HK40096830A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20220027981A (ko) 수면 문제를 치료하기 위한 렘보렉산트
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
JP2026512649A (ja) 疼痛の治療用化合物
EP3989976A1 (en) Lemborexant for treating sleep issues
WO2020263331A1 (en) Lemborexant for treating sleep issues
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted